HRT Financial’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

HRT Financial’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-66,098	Closed	-$202K	–	3738
2022 Q2	$202K	Buy	+66,098	New	+$404K	﹤0.01%	2243
2022 Q1	–	Sell	-69,962	Closed	-$1.15M	–	4103
2021 Q4	$1.15M	Sell	69,962 -555	-0.8%	-$6.46K	0.01%	1005
2021 Q3	$701K	Hold	70,517	–	–	﹤0.01%	1710
2021 Q2	$705K	Hold	70,517	–	–	0.01%	1474
2021 Q1	$702K	Buy	+70,517	New	+$729K	0.01%	1522

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

HRT Financial's PRDS Position: Q3 2022 in Review

HRT Financial sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 66,098 shares — an estimated $202K sold.

HRT Financial first reported a position in PRDS in Q1 2021 and held it in 5 quarters. The position peaked at $1.15M in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

HRT Financial reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
HRT Financial sold 66,098 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $202K.
HRT Financial first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
HRT Financial's Pardes Biosciences, Inc. Common Stock position peaked at $1.15M in Q4 2021.
68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.